PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2009-06-22
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00925782
- Locations
- 🇺🇸
University of Kansas Medical Center/University of Kansas Cancer Center and Medical Pavillion, Kansas City, Kansas, United States
Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
- Conditions
- Bladder CancerBladder NeoplasmCarcinoma, Transitional Cell
- Interventions
- First Posted Date
- 2008-07-25
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00722553
- Locations
- 🇺🇸
University of Rochester Cancer Center, Rochester, New York, United States
🇺🇸Peachtree Hematology/Oncology Consultants, Atlanta, Georgia, United States
🇺🇸University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States
Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
- Conditions
- Cutaneous T-cell Lymphoma
- Interventions
- First Posted Date
- 2007-11-07
- Last Posted Date
- 2020-01-03
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT00554827
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
- Conditions
- Peripheral T-cell LymphomaHodgkin's LymphomaB-cell LymphomaWaldenstrom's MacroglobulinemiaRelapsed or Refractory Lymphoproliferative Malignancies
- Interventions
- Dietary Supplement: Vitamin B12Dietary Supplement: Folic Acid
- First Posted Date
- 2007-06-04
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 119
- Registration Number
- NCT00481871
- Locations
- 🇺🇸
The Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
- Conditions
- Peripheral T-cell Lymphoma
- First Posted Date
- 2006-08-16
- Last Posted Date
- 2019-12-19
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT00364923
- Locations
- 🇨🇦
British Columbia Cancer Agency, Vancouver, British Columbia, Canada
🇧🇪Cliniques Universitaire Saint-Luc, Brussels, Belgium
🇺🇸City of Hope National Medical Center, Duarte, California, United States
Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT00144963
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction
- Conditions
- Malignant Melanoma
- Interventions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT00145041
- Locations
- 🇺🇸
University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States